Plain-English translation of NCT05748093 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether osimertinib, a medication used to treat advanced lung cancer with a specific genetic mutation, can work better when taken with a booster drug called . The booster helps your body absorb more of the medication, which could mean you need less of it while still fighting your cancer effectively. Researchers hope this approach will make the treatment more affordable without sacrificing how well it works.
Osimertinib is an excellent treatment for certain lung cancers, but it is extremely expensive—costing over €70,000 per year. Healthcare systems are struggling with the rising costs of new cancer medications. This trial is designed to see if a booster drug can help the treatment work at lower doses, reducing costs while maintaining the same benefit to patients.
Depending on which group you join, you will take osimertinib with the booster drug and have regular blood tests to measure how much medication is in your bloodstream. Your doctor will then personalize your treatment dose based on these results. Some participants may also be monitored for how well the medication reaches the brain if they have cancer spread there. The trial involves visits for blood sampling and scans as part of your standard cancer care.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
Netherlands